1 asset in Nasopharyngeal Type Undifferentiated Carcinoma

Therapeutic assets addressing Nasopharyngeal Type Undifferentiated Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anti-Egfr Antibody-Drug Conjugate Mrg003 Nasopharyngeal Type Undifferentiated Carcinoma	Sun Yat-sen University	P1	CC (43)